United Therapeutics(FRA) UTH

Market Cap€18.93B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€436.50

-1.11%

-4.90Today

United Therapeutics Financials at a Glance

Market Cap

€18.93B

Revenue (TTM)

€2.70K

Net Income (TTM)

€1.12K

EPS (TTM)

€23.98

P/E Ratio

18.41

Dividend

€0.00

Beta (Volatility)

0.03 (Low)

Dividend

€0.00

Beta (Volatility)

0.03 (Low)

Price

€436.50

Volume

Open

€436.50

Price

€436.50

Volume

Open

€436.50

Previous Close

€441.40

Daily Range

€436.50 - €436.50

52-Week Range

€258.70 - €522.80

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.03 (Low)

Price

€436.50

Volume

Open

€436.50

Previous Close

€441.40

Daily Range

€436.50 - €436.50

52-Week Range

€258.70 - €522.80

Estimated Earnings Date

N/A

UTH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About United Therapeutics

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Industry

Biotechnology

Sector

Health Care

Employees

1,400

CEO

Martine A. Rothblatt, PhD, MBA

Website

www.unither.com

UTH Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

19.20%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

5.43%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€18.93B

Shares Outstanding

42.89M

Volume

Avg. Volume

3.394

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

United Therapeutics Performance Analysis

United Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 1,842,385,651	29.2%
2023	2023-12-31	EUR 2,152,868,753	16.9%
2024	2024-12-31	EUR 2,660,094,841	23.6%
2025	2025-12-31	EUR 2,820,097,627	6.0%

United Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR 14.27	67.7%
2023	2023-12-31	EUR 18.33	28.5%
2024	2024-12-31	EUR 22.78	24.3%
2025	2025-12-31	EUR 24.69	8.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€673.68

+1.0%

Gross Profit

€588.11

+0.9%

Gross Margin

87.30%

+1.0%

Market Cap

€18.93B

N/A

Market Cap/Employee

€14.41

N/A

Employees

1,400

N/A

Net Income

€286.40

+1.0%

EBITDA

€305.32

+0.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€1.40K

+2.8%

Total Debt

€0.00

N/A

Accounts Receivable

€271.41

+0.8%

Inventory

€169.51

+1.2%

Long Term Debt

€0.00

N/A

Short Term Debt

€0.00

N/A

Return on Assets

17.23%

+1.0%

Return on Invested Capital

15.20%

N/A

Free Cash Flow

€175.83

+2.0%

Operating Cash Flow

€269.25

+2.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

BIAFbioAffinity Technologies

BIAFbioAffinity Technologies$6.37+0.40%

NVDANvidia

NVDANvidia$217.93-0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.46-0.05%

INTCIntel

INTCIntel$88.68-0.01%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$105.97-0.06%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$69.58-0.03%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$52.10+0.06%

Questions About UTH

What is the current price of United Therapeutics?

United Therapeutics is trading at €436.50 per share.

What is the 52-week range for United Therapeutics?

Over the past 52 weeks, United Therapeutics has traded between €258.70 and €522.80.

How much debt does United Therapeutics have?

As of the most recent reporting period, United Therapeutics reported total debt of €0.00.

How much cash does United Therapeutics have on hand?

United Therapeutics reported €1.40B in cash and cash equivalents in its most recent financial results.

What is United Therapeutics’s dividend yield?

United Therapeutics does not currently have a dividend yield.

United Therapeutics(FRA) UTH

United Therapeutics Financials at a Glance

UTH News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About United Therapeutics

UTH Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

United Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About UTH

What is the current price of United Therapeutics?

What is the 52-week range for United Therapeutics?

How much debt does United Therapeutics have?

How much cash does United Therapeutics have on hand?

What is United Therapeutics’s dividend yield?

Premium Investing Services